The Pros of Genetic Engineering: Why ‘Playing God’ Could Help The Human Race – RedOrbit
By Dr. Matthew Watson
RedOrbit | The Pros of Genetic Engineering: Why 'Playing God' Could Help The Human Race RedOrbit Despite the frequently encountered argument that scientists are 'playing God' with nature, the pros of genetic engineering are numerous and significant. When discussing genetically modified organisms (GMO), it is important to note that the FDA and the ... GMO's Do you know what you're eating? Flounder in Tomatoes? Should food ...Cornwall Free News Protesters demonstrate at FDA against GMOsWJLA Genetically Modified Organisms Split Genes, and OpinionsWWNO |
Gwynne Dyer: Genetic engineering: Golden rice – Lincoln Journal Star
By Dr. Matthew Watson
ThinkProgress | Gwynne Dyer: Genetic engineering: Golden rice Lincoln Journal Star Fourteen years ago, scientists developed a genetically engineered version of rice that would promote the production of vitamin A to counter blindness and other diseases in children in developing countries. In a few months, the Philippines will become ... GMO Rider: 'Monsanto Protection' or 'Farmer Sustainability'?Genetic Engineering News |
The Mystery about Cyanide Taste
By Dr. Matthew Watson
What is potassium cyanide??
A chemical compound with the chemical formula KCN is commonly known as the Potassium cyanide. This is a colorless crystalline compound, highly soluble in water and is similar in appearance as that of sugar. Potassium cyanide is considered to be highly toxic in nature. Potassium cyanide is considered to be one of the most deadly compounds being discovered till date.
Production of Potassium Cyanide:
Potassium Cyanide can be produced mainly by treating hydrogen cyanide in the presence of a fifty percent of an aqueous solution of potassium hydroxide. After that the aqueous solution is either evaporated in a vacuum or by treating the form amide in the presence of potassium hydroxide. On an average per year approximately fifty thousand tons of potassium cyanide are being produced all over the world.
Use of Potassium Cyanide:
Potassium Cyanide is mainly used for the purpose of electroplating, organic synthesis of a number of chemical compounds, gold mining and so on. In accordance with the large scale use of Potassium Cyanide, it is also used in smaller scale applications like in the jewelry manufacturing industry for chemical buffing and gliding. Other than those mentioned earlier, Potassium Cyanide is also used by the entomologists as it is an excellent killing agent, and it has the unique capability of causing minimum damage to the highly fragile specimens.
Mystery about Potassium Cyanide:
Since, the time of its invention, the biggest mystery that has been surrounded with Potassium Cyanide, is about the taste of it. Due to the fact that Potassium Cyanide is exceedingly poisonous substance and can cause death of a person in seconds, the taste of it has remained a mystery or a fact yet to be known to the world. Though, many researches and tests have been conducted to find the taste of Potassium Cyanide but none of them could come up with the appropriate result.
Different views about the taste of Potassium Cyanide:
There has been number of views among the scientists about the taste of the Potassium Cyanide, some of them are as follows:
· Since on hydrolysis of KCN, the resultant compound that are formed are KOH and HCN, which are strong base and weak base respectively, Potassium Cyanide is confirmed to be basic nature. Since at room temperature HCN is a gas which evolves and the solution is expected to have more KOH, so the taste of Potassium Cyanide is assumed to be bitter.
· Some, scientists who have died while finding the taste of Potassium cyanide, could only write the alphabet “S” before dying, so it is not conclusive whether it is sour, sweet or salty in taste.
Conclusion:
Though, a huge number of scientists sacrificed their lives in order to find the taste of Potassium cyanide, but it remained a mystery for long, until and unless a goldsmith from India named MP Prasad in an attempt to commit suicide with the help of Potassium cyanide could finally reveal the taste of Potassium cyanide. As per the suicide note of him the taste of Potassium Cyanide is very much acrid, that is irritatingly harsh and sharp. This fact about the taste of Potassium cyanide is approved by the World Health Organization and is marked as an extraordinary discovery in the field of science.
Source:
http://www.biotechblog.org/entry/mystery-cyanide-taste/
Editorial: Proposed cuts in state funding for NC Biotechnology Center would … – Winston-Salem Journal
By Dr. Matthew Watson
Editorial: Proposed cuts in state funding for NC Biotechnology Center would ... Winston-Salem Journal The governor's proposed budget would cut $10 million from the N.C. Biotechnology Center's $17.2 million annual appropriation over each of the next two years, the Journal's Richard Craver reported. The nonprofit center, whose only funding resource is ... |
Top Photos & Videos – News & Observer
By Dr. Matthew Watson
NewNet | Top Photos & Videos News & Observer A fledgling agricultural biotechnology company founded by a group of industry veterans and serial entrepreneurs has raised $14.5 million in venture capital financing in spite of a notoriously tough funding environment. “It's a testament to how good the ... RTP agri-tech bags $14.5M for crop researchTriangle Business Journal AgBiome Adds $14.5M for Agricultural ProductsPrivate Equity Hub (press release) |
Consortium for Plant Biotechnology Research rips off writer, threatens to sue … – Boing Boing
By Dr. Matthew Watson
Boing Boing | Consortium for Plant Biotechnology Research rips off writer, threatens to sue ... Boing Boing But not in the case of The Consortium for Plant Biotechnology Research, Inc., a company that receives millions in federal grants to fund biotech research. When Purrington sent CPBR an email telling them off for plagiarizing him, they responded by ... |
Biotechnology Industry Leader Mark Lievonen Honoured – Business Wire (press release)
By Dr. Matthew Watson
Canada NewsWire (press release) | Biotechnology Industry Leader Mark Lievonen Honoured Business Wire (press release) OTTAWA, Ontario--(BUSINESS WIRE)--On behalf of the biotechnology industry in Canada we congratulate Mark Lievonen, President of Sanofi Pasteur Limited for his recent induction to the Canadian Marketing Healthcare Hall of Fame Award, in recognition ... Sanofi Pasteur's Mark Lievonen Honoured For Commitment to Biotechnology ...Canada NewsWire (press release) |
Dow AgroSciences Unveils Biotechnology Research Center – Hoosier Ag Today
By Dr. Matthew Watson
Dow AgroSciences Unveils Biotechnology Research Center Hoosier Ag Today Dow AgroSciences officially cut the ribbon on their new biotechnology research center. The 19 acre facility houses over 200 researchers working with some of the most sophisticated and up-to-date technology in the world, all with the goal of increasing ... Dow AgroSciences opens new facility at global headquartersR & D Magazine |
Science of genome-sequencing has rocketed forward in 10 years – Milwaukee Journal Sentinel
By Dr. Matthew Watson
Science of genome-sequencing has rocketed forward in 10 years Milwaukee Journal Sentinel Howard Jacob, who has directed the sequencing efforts as head of the Medical College's human and molecular genetics center, has begun seeking support for an ambitious $60 million institute that would include clinical and research programs, data storage ... |
Dutch and Russian universities set up stem cell research centre – Telegraph.co.uk
By Dr. Matthew Watson
Telegraph.co.uk | Dutch and Russian universities set up stem cell research centre Telegraph.co.uk The 2012 Nobel Prize was awarded for the discovery that mature cells can be reprogrammed to become pluripotent (stem cells) by scientists in Japan and the UK ,and Skoltech has engaged one of the world's leading experts in cancer and molecular genetics ... |
Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV … – Science Careers Blog (subscription)
By Dr. Matthew Watson
Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV ... Science Careers Blog (subscription) 1Department of Microbiology, Immunology and Molecular Genetics and the UCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. 2Division of Pulmonary and Critical Care Medicine ... |
Science under the stage lights – Harvard Gazette
By Dr. Matthew Watson
Harvard Gazette | Science under the stage lights Harvard Gazette The American Cancer Society Professor in the Department of Microbiology and Molecular Genetics at Harvard Medical School first fell in love with the art form during a production of Samuel Beckett's absurdist play “Waiting for Godot.” But it wasn't ... |
UCLA study suggests potential therapy for HIV – Eureka! Science News
By Dr. Matthew Watson
Eureka! Science News | UCLA study suggests potential therapy for HIV Eureka! Science News ... they produce type-1 interferons, which trigger the immune system's protective defenses and sets off an alarm to notify surrounding cells," explained principal investigator David Brooks, assistant professor of microbiology, immunology and molecular ... |
Food Supplement Could Help Delay Parkinsons Disease – The Future of Things
By Dr. Matthew Watson
The Future of Things | Food Supplement Could Help Delay Parkinsons Disease The Future of Things A team of researchers from the Department of Human Molecular Genetics and Biochemistry in the Tel Aviv University (TAU) led by Prof. Gil Ast and Dr. Ron Buchner and recently discovered that a supplement known as phosphatidylserine can improve the ... |
StemCells, Inc., Nails Down Controversial, $19 Million Award from California Stem Cell Agency
By Dr. Matthew Watson
The stock price of StemCells, Inc.,
price today jumped as much as 9 percent after the company disclosed
it had finally concluded an agreement with the California stem cell
agency for a $19.3 million forgivable loan for research twice rejected by the agency's scientific reviewers..
cash was withheld until the financially strapped company could
demonstrate that it could match the size of the loan, as promised in
its application.
was nixed two times in 2012 by the agency's scientific reviewers who gave it a
score of 61. In a controversial move, the 29-member board approved the award in early September on a 7-5 vote after former agency
chairman Robert Klein intervened publicly on behalf of the firm. It was the first time that Klein had lobbied the board publicly on behalf of an application. It was also the first time that the board
approved an application that was rejected twice by its reviewers, a
panel of internationally recognized stem cell scientists.
CEO of StemCells, Inc., said,
"With CIRM's support, we are now
able to lay the groundwork that could result in the world's first
neural stem cell trial in Alzheimer's patients."
state research agency were tight-lipped about the nature of the
matching funds from the company, which reported losses of $28.5
million in 2012 on revenues of $1.4 million.
California Stem Cell Report, McGlynn said,
“At this time, we
do not intend to elaborate any further on the contents of our press
releases or public filings pertaining to the SVB (Silicon Valley Bank) or CIRM(the stem cell agency) loans.”
and the stem cell agency did not answer a question about whether
those funds are being used to back the award from California
taxpayers.
providing $19.3 million in matching resources. But Kevin McCormack,
senior director of public communications, did not provide any
specifics on the nature of the match. He only said,
“The matching requires
them to demonstrate they have enough funds necessary to
fund SCI’s share going forward as well as their own
operations and other commitments.”
million. We have queried the agency about the smaller figure
announced today.
$1.77 at the time of this writing. Its 52 week high is $2.67, and its
52 week low is $0.59. The loan from Silicon Valley Bank gives the
bank warrants to purchase 293,531 shares of the company at $1.70 over
the next 10 years.
company, which said its “obligation to repay the loan will be
contingent upon the success” of the research. If a product is
developed, it will take years before it could hit the market.
the stem cell agency in a touchy situation involving the company's decision last month to reject an additional $20 million award from
the agency.( It was the first time a recipient has rejected an award.) Neither the company nor the agency would give a reason for
the rejection of the loan for a spinal injury project . However, the
award also required a $20 million match, which undoubtedly tested the company's resources.
scored at 79 by agency reviewers and was routinely approved by the
board. With its withdrawal by the company, the agency, which prides
itself on funding only the best science, was left supporting research
(StemCells, Inc.'s Alzheimer's project) judged significantly inferior
by reviewers with its score of 61.
situation, CIRM's McCormack said,
“Our goal is to always fund the best,
most promising science. This is not the first time that our board has
voted to fund a project that the Grants Review Group had not
recommended (this has happened in around 2% of cases) The board did
so for a number of reasons, not the least of which is that this was
the first disease team application that had a goal of moving a
promising stem cell therapy for Alzheimer's towards clinical
trials.”
two points higher than the one from StemCells, Inc. Reviewers also did not recommend funding that application.
agency board came only after it publicly said the funds would not be
distributed until the StemCells, Inc., could show it could provide
the match, still another first for the agency.
the Los Angeles Times by Pulitzer Prize winning writer Michael
Hiltzik, who said in October that the
process was “redolent of cronyism.” He said a “charmed
relationship” existed among StemCells, Inc., its “powerful
friends” and the stem cell agency.
Stanford researcher Irv Weissman, who was a major fundraiser for
Proposition 71, which created the stem cell agency in 2004. Klein
headed the ballot campaign, which spent more than $30 million to win
voter approval. Weissman sits on board of directors of StemCells,
Inc., and holds 124,608 shares in the firm, including 8,630 he reported this month receiving.
Modest Approval from Long-time Stem Cell Agency Critic
By Dr. Matthew Watson
Of all California's newspapers, The
Sacramento Bee, the only daily paper in the state capital, has long
been the most critical – editorially – of the Golden State's $3
billion stem cell research agency.
modest nod of approval to the agency's modest efforts to clean up its
built-in conflicts of interest, which have been cited as a major flaw
by the prestigious Institute of Medicine.
“Stem cell agency finally addresses
potential for conflicts”
chairman of the agency, “has taken important steps in
reducing the potential for conflicts within this agency.”
“He hasn't
gone as far as we would like, or that independent outside reviewers
have recommended....But he's achieved what's possible, at least for
now, and the board may empower him to go further.”
in which the agency's governing board decided, among other things,
that 13 of the 15 board members linked to recipient institutions
could not vote on any grants, although they could participate in
discussion of applications. Twenty-nine persons sit on the board. In
a $700,000 report commissioned by the agency, the Institute of
Medicine recommended a fully independent board.
“We
think Thomas and the oversight board should go further and adopt the
Institute of Medicine recommendations. But that is politically
unlikely. As is now obvious, it will be up to the Legislature to
fully remove representatives of funding-eligible institutions from
being involved in decisions about grants that could come back to
them.
“Thomas, to his credit, recognizes
that his compromise may not be the perfect solution. He wants to test
out the new policy for a year, and see how it works. There's a lot
riding on the outcome. CIRM is expected to run out of funds in 2017,
and while philanthropy and foundation money could extend that for a
few years, supporters of California stem cell research clearly want
to go back to the ballot to seek additional funding. To make that
case, CIRM supporters can't afford any more scandals about insider
dealing. The next year will reveal whether it is on the right track.”
Vatican Conference Hopes to Promote Truth on Adult Stem Cell Therapy
By Sykes24Tracey
Doctors, Patients Speak on Personal Experiences Vatican City, April 11, 2013 (Zenit.org) Junno Arocho Esteves | 380 hits
During todays first session of the Second International Vatican Adult Stem Cell Conference, scientists, doctors and patients had an opportunity to share not only the advances in adult stem cell research, but also the potential it has to transform modern day health care.
The ethical debate on the use of embryonic stem cells has, according to Dr. Robin Smith, stifled the advances made in adult stem cells, which are derived from adult tissue samples. Dr. Smith serves as president of the Stem for Life Foundation as well as CEO of NeoStem, a leading developer in cellular therapy.
Stem Cell Therapy, especially using cultivated adult stem cells , can be used to regenerate dying tissue in the body of a person suffering debilitating diseases, such as Alzheimers, Parkinsons, or Multiple Sclerosis (MS).
In November 2001, we kicked of the first Stem Cell Conference. Since then, the entire world has awakened.
By improving the clinical outcomes, we can save hundreds of millions of lives, she said. We're not talking about medications, she continued. Were talking about repairing the heart with adult stem cells. Re-inserting these cells into a damaged organ is turning back the clock. In just 17 months, we have seen stunning advancements in leukemia treatments.
The work in stem cell research has only begun to be understood. The last conference did not have panels that discussed the benefits of cellular therapy on MS and diabetes. Dr. Smith stated that in the United States, $245 billion is spent on managing diabetes, which can cause blindness, stroke and amputations which is only getting worse.
Cellular therapy has the potential to rewrite the history of this disease, she said. Adult stem cells is something we can all agree upon; they are ethically pure. We can grasp whats inside of us and introduce them into the body.
The purpose of the conference, she concluded, was meant to inspire change and to promote the truth and promise behind stem cell science. We hope to show that you no longer have to choose between science and faith.
In Search of Hope
Read more from the original source:
Vatican Conference Hopes to Promote Truth on Adult Stem Cell Therapy
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. – Video
By Dr. Matthew Watson
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Power and movements in the finger...
By: neurogenbsi
Continued here:
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video
Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. – Video
By NEVAGiles23
Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1) Patient had a fall on 31st December 2012 due to whi...
By: neurogenbsi
Go here to read the rest:
Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. - Video
Stem Cell Therapy Treatment for Inclusive Body Myopathy by Dr Alok Sharma, Mumbai, India. Part 2 – Video
By Dr. Matthew Watson
Stem Cell Therapy Treatment for Inclusive Body Myopathy by Dr Alok Sharma, Mumbai, India. Part 2
By: neurogenbsi
Continued here:
Stem Cell Therapy Treatment for Inclusive Body Myopathy by Dr Alok Sharma, Mumbai, India. Part 2 - Video